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Abstract
Background:  Domperidone, a drug that enhances upper gastric motility, is an anti-dopaminergic
medication that also elevates prolactin levels. It has been shown to safely increase the milk supply of
lactating women. To date, researchers have analyzed the effects of domperidone on lactating woman with
respect to the quantity of their milk production, adverse effects, and drug levels in the breast milk.
However, the effect of domperidone on the macronutrient composition of breast milk has not been
studied and current guidelines for fortification of human milk for premature infants do not distinguish
between those women using or those not using domperidone. The purpose of this study is to evaluate the
effect of domperidone (given to lactating mothers of very preterm infants) on the macronutrient
composition of breast milk.
Methods/Design: Mothers of infants delivered at less than 31 weeks gestation, who are at least 3 weeks
postpartum, and experiencing lactational failure despite non-pharmacological interventions, will be
randomized to receive domperidone (10 mg three times daily) or placebo for a 14-day period.
Breast milk samples will be obtained the day prior to beginning treatment and on days 4, 7 and 14. The
macronutrient (protein, fat, carbohydrate and energy) and macromineral content (calcium, phosphorus
and sodium) will be analyzed and compared between the two groups. Additional outcome measures will
include milk volumes, serum prolactin levels (measured on days 0, 4, and 10), daily infant weights and
breastfeeding rates at 2 weeks post study completion and at discharge. Forty-four participants will be
recruited into the study. Analysis will be carried out using the intention to treat approach.
Discussion: If domperidone causes significant changes to the nutrient content of breast milk, an alteration
in feeding practices for preterm infants may need to be made in order to optimize growth, nutrition and
neurodevelopment outcomes.
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Background
During the past two decades, significant advances in med-
ical technology have contributed to the increased survival
of preterm, very low birth weight infants. As mortality
rates have declined, the focus has shifted to decreasing
morbidity and length of hospital stay for these high-risk
infants. Nutritional care is one area with great potential
for improvement. There continue to be many unanswered
questions as to what constitutes optimal nutrient intake
for the extremely preterm neonate. Although the current
literature states that fortified human breast milk is most
desirable [1-6], the optimal macronutrient composition
of prepared fortifiers continues to be studied [7]. Also, the
shift from formula feeding of preterm infants to human
breast milk has caused an increase in mothers of preterm
infants providing expressed breast to their babies over
prolonged periods.
Many mothers of very preterm infants experience diffi-
culty maintaining milk production over several months,
and hence medications such as domperidone are often
recommended to help augment milk supply. Such medi-
cations increase maternal prolactin levels and have been
shown to significantly increase the quantity of breast milk
a lactating woman produces [8-18]. Higher prolactin lev-
els have been linked to accelerated decline in protein lev-
els in term breast milk [19,21]. However, there is a paucity
of information in the literature, on the effect of domperi-
done on the macronutrient content of breast milk.
Although pharmacological augmentation of breast milk
volume is valuable, carefully conducted quantitative stud-
ies are required to assess the effect of such medication on
human breast milk composition including protein, fat
and other constituents. We, therefore, designed a study to
determine the effect of domperidone on the macronutri-
ent (protein, fat, and energy) and macromineral (calcium,
phosphorus, and sodium) content of breast milk among
mothers of very preterm infants.
Summary of literature review
a. Advantages of human breast milk
Breast milk is generally considered to be the optimal form
of nutrition for all infants regardless of gestational age
[1,2]. Preterm infants have better outcomes if they receive
human breast milk during the first months after birth.
Human breast milk provides both nutritive and nonnutri-
tive benefits to preterm infants. Nutritive benefits include
a whey predominant protein source, which is more easily
digested and promotes more rapid gastric emptying.
Human milk is also a source of the very long chain fatty
acids, which are important components of brain and red
cell membranes. Nonnutritive advantages include psycho-
logical benefits of maternal-infant bonding, improved
gastrointestinal outcomes, reduced risk of atopic eczema,
and fewer systemic infections during initial hospitaliza-
tion, [3-7,24-28] as well as, improved psychomotor devel-
opment [26-29].
b. Expressed breast milk
Increasingly, mothers of premature babies being cared for
in neonatal intensive care units are asked to provide
expressed human breast milk for their babies. Most moth-
ers express a strong desire to provide breast milk for their
infant and verbalize positive feelings about being able to
do something to help their ill baby. However, many
mothers of very preterm infants find it difficult to provide
adequate amounts of expressed breast milk to meet their
baby's needs over prolonged periods of time. Stress
related to the hospitalization, concerns related to the
increased risk of mortality and morbidity, separation, and
lack of infant suckling may contribute to decreased milk
production [33]. Decreased milk production among
mothers of very preterm infants expressing breast milk can
occur as early as two weeks postpartum, although such
problems typically peak between four and six weeks post-
partum [8,33].
c. Physiology of lactation
The initiation of lactation (lactogenesis) is a natural proc-
ess that is based on a complex interaction of hormones.
Changes in estrogen and progesterone during pregnancy
alter the morphologic structure of breast tissue. Increasing
levels of the hormone prolactin is key in the initiation and
maintenance of lactation [34,35] and may play a role in
the control of electrolyte composition [20,21] and altera-
tion in amino acid concentration [19] of mature human
breast milk. A significant increase in lactogenesis occurs
following delivery with the concurrent decline in estrogen
and progesterone. In addition, the tactile stimulus by the
suckling baby causes a release of prolactin from the pitui-
tary, which stimulates milk flow. This suckling induced
prolactin release is a reflex related to hypothalamic serot-
oninergic neuron activation, accompanied by a concomi-
tant increase of dopamine turn over [34,35]. Babies
delivered at less than 32 weeks gestation are not able to
effectively coordinate sucking, swallowing and breathing
[36]. The lack of effective suckling that is associated with
the delivery of a preterm baby as well as maternal stress,
infection, or fatigue can lead to difficulties maintaining
lactation [8,33].
d. Non-pharmacological interventions to enhance human 
breast milk production
Non pharmacological measures such as added emotional
support, kangaroo care/skin to skin, compressing and
massage, relaxation techniques, expressing breast milk at
the baby's bedside, increasing pumping times, and altera-
tions in mechanical expression contribute to a variable
level of success in augmenting milk production [9,37]. For
those mothers whose milk production is refractory toBMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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non-pharmacological interventions, and who verbalize a
continued desire to provide expressed breast milk, the use
of pharmacological intervention may be recommended.
e. Pharmacological interventions
The administration of an anti-dopaminergic drug, such as
metoclopramide or domperidone has been shown to
yield positive results. Endogenous dopamine has a physi-
ological inhibitory role in the control of prolactin release.
Therefore, the administration of a dopamine inhibitor
increases plasma prolactin levels and induces lactogenesis
[9]. Metoclopramide, a central dopamine antagonist, has
been most widely studied and proven to be highly effica-
cious in augmenting milk supply [8,10-14]. However,
reports indicate that it crosses the blood brain barrier, and
is secreted in significant amounts in the breast milk [12].
As well, animal studies have reported dopamine mediated
responses in the offspring of nursing rats [38].
f. Why choose domperidone?
Both metaclopramide and domperidone are anti-
dopaminergic drugs. Both induce lactation by inhibiting
endogenous dopamine and thereby increasing plasma
prolactin levels. Domperidone is a newly developed anti-
emetic with no structural relationship to the phenothi-
azine anti-emetics and metoclopramide; it is structurally
related to the neuroleptic drug droperidol. Domperidone
is a dopamine antagonist in vitro; it binds strongly to the
dopamine (DA) receptors of the striatal area [40]. It is felt
the domperidone inhibits dopamine receptors at either
the level of the anterior pituitary median eminence or at
the tuberoinfundibular systems, both of which are outside
the blood brain barrier. This differs significantly from
metoclopramide, which inhibits dopamine (DA) cen-
trally [9]. Domperidone is less lipid soluble, has a higher
molecular weight and has lower protein binding as com-
pared with metoclopramide [84]. These characteristics
may also prevent domperidone from crossing the blood
brain barrier, thus causing less extra pyramidal effects that
are more commonly reported with the use of metoclopra-
mide.
Thus, domperidone, a peripheral dopamine antagonist,
may be safer than metoclopramide [39]. Drug levels of
domperidone in breast milk are also significantly lower
than metoclopramide (p < 0.05) [15,16]. Studies have
shown that breast milk samples taken from women
receiving either a 10 mg dose of domperidone or a 10 mg
dose of metoclopramide contained 10.3 ng/ml of dom-
peridone and 68.5 ng/ml of metoclopramide (p < 0.05)
[16]. Domperidone has been shown to significantly
increase milk production without evidence of adverse
effects in the infant [15-18]. Domperidone has been
shown to raise the serum prolactin level in non-lactating
women from 8.1 to 110.9 ng/ml after one 20 mg dose
[40]. In a double-blind placebo controlled trial, 32 moth-
ers of full term infants experiencing failure of lactogenesis
were randomized to receive either domperidone (10 mg
TID) or placebo. Prolactin levels were reported as signifi-
cantly higher after the 2nd day of treatment in the dom-
peridone group (p < 0.01). The mean daily milk yield was
also increased significantly in the domperidone group (P
< 0.01), with a corresponding higher infant weight gain
[18]. In a small double blind, randomized controlled trial
(n = 16), a 7 day course of domperidone (10 mg TID)
given to mothers of preterm infants experiencing insuffi-
cient milk production resulted in a significantly increased
milk supply (P < 0.05), low levels of drug detected in
breast milk (< 0.2 mcg/kg/d) and significantly higher
maternal prolactin level when compared to the placebo
group [17]. No infant or maternal side effects were
reported in the above trials. Both the Canadian and Amer-
ican Academy of Pediatrics have approved the use of dom-
peridone for breast-feeding mothers [41].
g. Fortification of human breast milk
Despite the numerous advantages of human breast milk,
the exclusive feeding of human breast milk to premature
infants has been associated with lower rates of growth,
nutritional deficits, and prolonged hospital stays [42-51].
Commercial formulas for preterm infants have been
designed to meet the nutritional needs of such infants but
cannot provide the infant with the advantages of human
milk [3-7,22-32]. Therefore, it is generally recommended
that breast milk feeds for preterm infants be fortified with
a commercially available human milk fortifier (HMF)
[2,7,52,53]. The inadequate intake of protein, energy, cal-
cium, and phosphorus related to unfortified breast milk
has been cited as the main reason for the need for fortifiers
[42-50,55-58]. Infant fortifiers provide supplemental
amounts of calories, protein, vitamins, minerals and trace
elements to human breast milk in order to best meet the
nutritional needs of the preterm infants.
Preterm infants are born with low skeletal stores of cal-
cium and phosphate. They have increased requirements
for these minerals in order to ensure adequate postnatal
skeletal growth. Poor radiological bone mineralization,
rickets and fractures have been described in premature
infants receiving breast alone [55,56,58]. Supplementa-
tion of calcium and phosphorous has been shown to nor-
malize biochemical indices, serum calcium, and serum
phosphorus, as well as normal urinary excretion of cal-
cium and phosphorous [59-61]. Serum sodium levels also
normalize following supplementation [57].
Protein and energy supplementation has been associated
with improved rates of weight gain and better indices of
protein nutritional status [49]. The Cochrane review on
protein supplementation states that protein supplementa-BMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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tion of preterm mothers milk increases short-term weight
gain: weighted mean difference 3.6 g/kg/day, 95% CI 2.4
to 4.8 g/kg/day, linear growth 0.28 cm/week, 95% CI 0.18
to 0.38 cm/week, and head growth 0.15 cm/week, 95% CI
0.06 to 0.23 cm/week. Blood urea levels also increase with
protein supplementation 1.0 mmol/l, 95% CI 0.8 to 2.1
mmol/l [62]. Current supplemental feeding practices are
calculated based on anticipated macronutrient and elec-
trolyte composition of preterm mother's milk that is not
being augmented by medication.
h. Breast milk composition
Human breast milk composition is widely variable both
within and between breast-feeding mothers [63]. Varia-
tion in macronutrient composition can occur at various
feeding times throughout the day or night and also at the
beginning and end of a feed [64]. These variations have
been reported to be greater in mothers of preterm infants
providing expressed breast milk. Measuring samples taken
from pooled 24-hour collections may limit the degree of
variability reported. Variation in the composition of
human breast milk has been associated with the diagnosis
of either sporadic or chronic mastitis. The sodium content
of the breast milk is the constituent most profoundly
affected [66].
The composition of preterm mother's milk also differs
from that of term mother's milk [67-69]. Although pro-
tein levels are initially higher in preterm breast milk, the
natural temporal decline of protein content creates a
nutritional deficit when compared to the needs of the pre-
term infant [5]. Studies show that there is a decline in pro-
tein content following delivery, while fat, lactose and
energy content increases. These trends are more pro-
nounced during the first 3 weeks and are greatest in the
preterm group [64]. In a more recent study, random spot
samples of breast milk from mothers of premature infants
were analyzed to estimate macronutrient variability.
Although fat content was highly variable within and
between individuals, it remained fairly constant through-
out lactation. Protein was less variable but was found to
decrease significantly throughout the first four weeks of
lactation (r = -0.45, p < 0.001), then continued to fall at a
slower rate of decline over time and with increased vol-
umes of breast milk [70]. Several studies have reported
similar findings [67,70-74].
Maas [74] studied the effects of gestational age (GA), post-
natal age (PNA), and post-menstrual (PMA = GA+PNA)
on the macronutrient composition of very preterm moth-
ers milk. Total nitrogen, fat, lactose and carbohydrate con-
centrations, energy density and 24-hour volume were
determined from 282 (24 hour) samples collected (day 7–
55) from seventy mothers of premature infants (25–29
weeks gestation) [74]. The major findings of the study
were that developmental changes in milk composition are
largely determined by PNA, minimally by GA and not at
all by PMA. Milk volume (24 h) itself did not show a
dependence on GA, PNA or PMA. When volume was used
as a time varying covariate in the analysis, total nitrogen
content decreased while lactose and carbohydrate content
increased when 24-hour milk volume increased. These
findings were in accordance with the literature [70,71,73].
There have been two studies examining the effect of meto-
clopramide on macronutrient content and sodium con-
tent of term mother's milk. When term breast milk
samples from primiparous women taking metoclopra-
mide were compared to samples from a similar group tak-
ing a placebo, the expected decline in protein content
occurred at an accelerated rate in the treatment group
[19]. Sodium concentration in term human breast milk
was compared in a smaller study using a similar design to
determine the effect of metoclopramide. No significant
differences were detected between groups. The small sam-
ple size (n = 22) and lack of data regarding calcium and
phosphorus levels warrant further investigation in rela-
tion to preterm milk composition [21]. Since domperi-
done differs in structure and mechanism of action from
metoclopramide and since studies evaluating metoclopra-
mide's effect on breast milk composition have been lim-
ited to term mother's milk, our study is both warranted
and necessary to ensure optimal infant nutrition.
Hypothesis
The macronutrient composition (protein, fat and calo-
ries) of human breast milk will be significantly altered by
the administration of domperidone.
Methods/Design
a. Objectives
The intent of this study is to evaluate the effect of dom-
peridone on the macronutrient composition of breast
milk among mothers of preterm infants. Potential
changes in protein, fat, lactose, energy, calcium, phospho-
rus and sodium content in expressed breast milk will be
assessed. Secondary objectives include assessment of the
effect of domperidone on breast milk volume, prolactin
level, daily infant weight, and breastfeeding rates 2 weeks
after treatment completion and at discharge.
b. Study design
We propose to carry out a randomized double-blind pla-
cebo-controlled study comparing the effect of domperi-
done use on the macronutrient composition of preterm
mother's milk.
c. Study population
The source population consists of mothers of preterm
infants delivered at less than 31 weeks gestational ageBMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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admitted to the Neonatal Intensive Care Unit at the IWK
Health Centre who are providing expressed breast milk to
their infants and who experience lactational failure three
weeks after delivery.
d. Inclusion criteria
i. Mother of an infant born less than 31 weeks gestation
ii. Women mechanically expressing breast milk using a
double collecting system
iii. Experiencing lactation failure indicated by at least one
of the following:
A decreasing milk supply (by greater than 30 percent from
peak volume based on maternal account)
An inability to provide adequate breast milk to meet the
daily nutritional intake of their infant
iv. Women who have had little or no improvement in
milk production following education/counseling with a
lactation consultant/Neonatal Intensive Care nurse with
respect to non-pharmacological techniques.
v. Postpartum period equal to or greater than three weeks.
e. Selection criteria for study subjects
Women who meet the inclusion criteria will be
approached by the study investigator/nurse, informed of
the study. Signed written informed consent will be
obtained.
f. Exclusion criteria
i. Participants receiving any medication known to alter the
effect of domperidone (e.g. cimetidine, ranitidine, famo-
tidine, and nizatidine) or medication that interacts with
domperidone (e.g. haloperidol, lithium).
ii. Experiencing mastitis
iii. Having a chronic or debilitating illness.
iv. Previous breast surgery
v. Having a known lactose intolerance
Allocation of participants to the trial groups – 
see figure 1
Randomization
Eligible and consenting woman will be randomized in
blocks of four. Pharmacy staff will randomly (using a
computer based code) assign mothers to receive either
domperidone, 10 mg orally three times daily [17,38] or
placebo for a two week period. Mothers of infants >3 but
< 4 weeks postpartum will be randomized separately from
those ≥ 4 weeks postpartum in order to ensure identical
proportions within the domperidone and placebo groups
(i.e. randomizations will be stratified by postpartum
duration at study entry). Participants will receive their 2-
week drug or placebo supply following enrollment. They
will be provided with instruction related to self-adminis-
tration and asked to return the medication vial and any
unused medication at the completion of the two-week
period. The study nurse/investigators will be in close con-
tact with the mothers and review instruction related to
medication on study days 4, 7, and 14.
What are the proposed methods of protecting 
against sources of bias?
The double blind study design in which participants, neo-
natal staff, and study personnel will be blinded to group
enrollment will ensure that non-domperidone related
intervention effects and information collection is similar
between the drug and placebo groups. In order to have
similar presentation and appearance of domperidone and
placebo, domperidone tablets will be crushed and mixed
with lactose. The resulting powder will be placed in clear
capsules. Plain lactose powder will also be placed in clear
capsules to act as the placebo. Participants will receive a
two-week supply of either domperidone or placebo fol-
lowing randomization at no cost to them. Measured pro-
lactin levels will not be made available until the
completion of the study period.
What is the proposed duration of treatment?
The treatment period begins following randomization. It
consists of day 0 on which baseline measurements will be
taken and recorded, and a 14-day treatment period during
which domperidone (10 mg × 3/daily) or placebo (3/
daily) is administered.
What is the proposed frequency and duration of 
follow-up?
Breast milk samples will be obtained on day 0, 4, 7, and
14. Serum prolactin levels will be collected on days 0, 4,
and 14. Infant weights will be measured daily. Each par-
ticipant will be asked questions regarding breast-feeding
two weeks following discontinuation of the treatment and
at discharge.
What are the proposed outcome measures?
a. Primary outcome
The protein levels from breast milk, collected on days 0, 4,
7, and 14 will be compared, between the two groups (tak-
ing into consideration the expected rate of decline associ-
ated with increasing postpartum days).BMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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Allocation of Participants to the Trial Groups Figure 1
Allocation of Participants to the Trial Groups.
Mothers of 
infants < 
31 weeks 
admitted to 
NICU
Eligibility
Assessment
Consent
Not
Eligible
Refusal
Randomize
(stratified
and
blocked)
Domperidone
Group
Placebo Group
Outcomes
i. Primary outcomes
protein levels
ii. Secondary outcomes
fat, carbohydrate, lactose, 
energy, calcium,
phosphorus and sodium
iii. Other outcomes
Daily breast milk
volumes, serum prolactin 
levels, daily infant 
weights, and breastfeeding 
rates two weeks after
treatment completion and
at discharge.
Outcomes
i. Primary outcomes
protein levels
ii. Secondary outcomes
fat, carbohydrate, lactose, 
energy, calcium,
phosphorus and sodium
iii. Other outcomes
Daily breast milk
volumes), serum prolactin 
levels, daily infant 
weights, and breastfeeding 
rates two weeks after
treatment completion and
at discharge.BMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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b. Secondary outcomes
The fat, carbohydrate, lactose, energy, calcium, phospho-
rus and sodium content of breast milk, collected on days
0, 4, 7, and 14, will be compared between domperidone
and placebo groups.
c. Other outcomes
Daily breast milk volumes (if the infant breast feeds, vol-
ume will be estimated using pre and post feeding
weights), serum prolactin levels, daily infant weights, and
breastfeeding rates two weeks after treatment completion
and at discharge.
Sample size
Sample size was calculated using a 2-sided test, an alpha
error of 0.05 and a power of 80 percent. Based on the
medical literature and prior clinical understanding, we
designed the study to detect as significant a 20 percent or
greater change in protein content (in the domperidone
group relative to the placebo group). We will also have
sufficient power to detect a 20 percent or greater change in
fat content and a 10 percent or greater change in energy
content, if such differences are in fact caused by domperi-
done. Means and standard deviation values for protein,
fat and energy content used in the sample size calculation
were obtained from a recent, authoritative publication on
the breast milk content of preterm human milk [74].
Based on this calculation our study will recruit 44 partici-
pants, 22 assigned to the domperidone group and 22 to
the placebo group.
What is the planned recruitment rate?
In the year 2000, 58 surviving infants less than 31 weeks
gestation were admitted to the Neonatal Intensive Care
Unit. Of these 20–25 percent were multiple births. Breast-
feeding initiation rates are 80–85 percent in our nursery.
Due to the lack of information regarding the incidence of
lactation failure in this population, a convenience (2001)
survey of mothers of preterm infants providing breast
milk for their babies was carried out. Fifty-five percent of
these mothers had experienced lactation failure, several of
whom had been prescribed domperidone (domperidone
is not prescribed routinely in this centre). Therefore, 20–
23 women a year will be eligible for the study. Recruit-
ment rates for research studies in our NICU range from
60–100 percent. Based on previous studies done in this
setting where risk is minimal and side effects are rare, we
estimate a greater than 90 percent recruitment rate.
Will compliance be a concern?
Since side effects are rare, we do not anticipate problems
with compliance. The majority of mothers will be visiting
their baby on a regular basis, hence providing milk and
blood samples should not be a great inconvenience. Par-
ticipants will receive their 2-week supply of domperidone
or placebo following enrollment. They will be provided
with instruction related to self-administration and asked
to return the medication vial and any unused medication
at the completion of the two-week period. Pill counts will
be done in pharmacy to ensure drug accountability and
evaluate compliance. The study nurse/investigators will
be in close contact with the mothers and review instruc-
tion related to medication on study days 4, 7 and 14.
Based on our past clinical observations, we anticipate that
the majority of the participants enrolled will be mothers
of infants delivered between 24–28 weeks gestational age.
The infants will be 29–33 weeks corrected gestational age
at the end of the study period. Although many of these
infants will receive skin to skin care from their mothers
(kangaroo care), few will be actively breast feeding. For
those infants who are enrolled at a later gestational age
(who will be closer to 35 weeks at the end of the study
period) and able to begin breast-feeding, milk volumes
will be calculated using pre and post feeding weights.
Mothers will be asked to refrain from breast-feeding and
to express breast milk on days 0, 4, 7 and 14 as per our
usual practice to ensure that a 24-hour pooled breast milk
sample will be obtained. Recruitment and compliance
therefore will not be adversely affected.
What is the likely rate of loss to follow Up?
The Neonatal Intensive Care Unit (NICU) is the tertiary
level neonatal unit for all of Nova Scotia and for most of
the Maritime Provinces. Most babies in the NICU stay
until discharged from hospital. Approximately 20 percent
return to local hospitals prior to discharge home. How-
ever, very few are transferred prior to 35 weeks corrected
gestational age. Mothers of any infants transferred prior to
discharge will be provided with a toll free telephone
number and instructed to notify the principal investigator
or study nurse of their discharge home. Answers to follow-
up questions will be obtained by telephone by either the
principal investigator or study nurse. In addition, most
infants that meet inclusion criteria for this study (all Nova
Scotia and Prince Edward Island babies born at less than
31 weeks) continue to be followed until three years of age
as part of the IWK Perinatal Follow-up Program. This pro-
gram loses two to three percent to follow-up. We therefore
do not expect any significant losses to follow up.
What is the proposed type and frequency of 
analysis?
a. Method of breast milk collection
Throughout the study, breast milk will be expressed
according to the standard practice of the nursery. Breast
milk will collected using the Symphony reusable breast
pump (Medela Canada). Each participant will be supplied
with a double pump collecting system and sterile collec-
tion bottles. Each woman will be instructed to collect 24-BMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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hour samples of breast milk for the day prior to beginning
treatment and then each day for the two-week period. A
new container will be used for each pumping. Each partic-
ipant will keep a diary to record the amount of milk
pumped, the date and time as well as ensure that adhesive
labels with this information also be placed on each of the
containers. Daily milk volumes will be calculated. On
days 0, 4, 7 and 14, two small samples (1 ml and 30 mls)
of milk (from a pooled 24 hour collection) will be
retained for analysis. The remainder of the milk will be
available for the infant as usual.
b. Chemical analysis
Breast milk samples (24 h – pooled) will be frozen (-70 C)
and couriered in batches of eight for analysis of macronu-
trient content to the Prince Edward Island Food Technol-
ogy Centre. Total nitrogen will be determined using the
Kjeldahl method [75]; fat by the Roese-Gottlib method;
ash and moisture by Forced Air Oven: and, energy, carbo-
hydrate and lactose concentrations will be calculated [78].
Mineral content will be analyzed at the IWK Laboratory
Department. Samples will be centrifuged and the aqueous
component assayed [79]. Phosphorous content will be
measured using the Ammonium molybdate method on
the Ortho Vitros®) chemistry analyzer [80]. Calcium con-
tent will be determined using the Arseno (III) method on
the Ortho Vitros®) chemistry analyzer [81]. Sodium con-
tent will be determined by ion selective electrode [82].
Mothers will also be asked to provide blood samples to
determine prolactin concentrations prior to the initial
dose, on day four and day 14. Serum prolactin levels will
be collected at the IWK Health Centre outpatient tab and
measured using Chemiluminescence immunoassay on
the Vitros®) Eci analyzer [83]. Each participant will
receive, requisitions for blood collection dated for the
appropriate study days required. If a participant is unable
to come to the IWK Health Centre, the principle investiga-
tor or study nurse will make alternate arrangements with
her family doctor and local laboratory to ensure that the
specimen is collected.
c. Statistical analysis
Analysis and inference will be based on the intention-to-
treat principle. Efforts will be made to ensure that follow
up is complete for all subjects and that there are no miss-
ing values for any of the subjects for any variable. Blinding
of group assignment will be retained until after the analy-
sis is completed. Baseline characteristics of study subjects
will be contrasted to ascertain that randomization has in
fact produced comparable groups with respect to all vari-
ables that effect the composition of breast milk including
gestational age at delivery and duration since delivery. The
primary outcome of interest will be a potential decline in
breast milk protein content over time within the domperi-
done group versus the placebo group. This analysis will
compare the means in the two groups before and after
treatment and contrast the mean difference between
groups using 95 percent confidence intervals and a p
value. The stratified nature of the randomization will be
accounted for in the analysis. If differences are noted in
baseline characteristics, inferences will be made based on
observed and (linear regression) adjusted differences
between groups. Analysis for fat, lactose, energy, calcium,
phosphorus and sodium content in expressed breast milk
will be done in an identical fashion as for protein by com-
paring the means in the two groups before and after treat-
ment and contrasting the mean differences between
groups using 95 percent confidence intervals and a p
value. Prolactin levels will be compared between the two
groups and used to determine the correlation between
prolactin levels and volume of milk produced.
Trial management
The study nurse will assume the role of study coordinator.
She will be responsible for the day-to-day management of
the trial. The principal investigator will have an active role
in the trial and meet weekly with the study nurse.
Significance of study
To date, researchers have analyzed the effects of domperi-
done on lactating woman with respect to the quantity of
their milk production, adverse effects, and drug levels in
the breast milk. Currently, guidelines for fortification of
human milk for preterm infants do not distinguish
between women using or not using domperidone. Dom-
peridone causes an increase in maternal prolactin levels
and has been shown to significantly increase human
breast milk volumes. No study has examined the effect of
domperidone use (to augment lactation) on the composi-
tion of breast milk. The purpose of this study is to com-
pare the macronutrient and macro mineral composition
of breast milk between mothers of infants delivered at less
than 31 weeks gestation, receiving domperidone versus
placebo. If significant differences in nutrient content
occur between groups, alterations to current standards of
feeding practices for premature infants may need to be
made in order to optimize growth and nutrition. The
results of this study will provide clinicians with valuable
information to aid in guiding feeding practices for pre-
term infants.
Potential risks to the safety of participants 
involved in the study
a. Potential side effects of medication
Side effects associated with the use of oral domperidone
are extremely uncommon. Side effects that have been
reported include dry mouth, transient skin rash or itching,
headache, thirst, abdominal cramps, diarrhea, drowsinessBMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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and nervousness. These side effects have been reported
only occasionally (incidentally) and have been generally
associated with high dosages of the medication. Symp-
toms are usually minor and all symptoms disappear fol-
lowing discontinuation of the medication [41,76].
Domperidone is highly metabolized by CYP3A4 in the
liver, drug interactions related to its inhibition are
expected to occur. Cimetidine, ranitidine, famotidine,
and nizatidine may interfere with domperidone's bioa-
vailability and should not be co-administered [76]. Medi-
cations such as haloperidol and lithium when taken at the
same time as domperidone may cause exaggerated central
nervous system symptoms. Therefore, subjects who satisfy
eligibility criteria will not be invited to participate in this
study if they are taking any of these medications [76].
Low levels of domperidone are excreted in human breast
milk [36,38]. There are no reported cases of side effects in
infants. As previously mentioned, the Canadian and
American Academy of Pediatrics have approved its use in
breastfeeding mothers [41].
b. Confidentiality
Participant data collected during this trial will be kept
confidential and locked in a secure office area. Study staff
will have access to the data as well as participant's medical
records as they pertain to this study. A letter will be sent to
the participant's family doctor to inform him/her of their
participation in the study. Published results will not con-
tain any information that would identify individual par-
ticipants. Study records will be stored in a locked area and
will be kept for 10 years past the age of majority of the
infant.
Role of each investigator
MCY will be responsible for the progress and timely com-
pletion of the trial. MCY, ACA, VMA and JML will be
responsible for responding to clinical queries, encourag-
ing recruitment, protocol compliance and accurate and
complete data collection. KCD will be responsible for lab-
oratory related queries. VMA will be responsible for pre-
scribing medication and for providing advice regarding
participant's concerns or questions. ACA will be responsi-
ble for providing advice regarding neonatal issues. KSJ
will be responsible for providing advice on methodologi-
cal issues and assisting with interpreting statistical analy-
sis. Study investigators will be obliged to participate in
study committee meetings related to study progress and
completion.
Ethics
Informed consent will be obtained from the women prior
to study entry. The IWK Health Centre Research Ethics
Board has approved this study. Domperidone is consid-
ered safe for use in lactating women. Nevertheless, a care-
ful watch will be kept on all study participates with regard
to side effects of drug administration. Participants will be
made aware of possible side effects and given contact
numbers in the event they experience an adverse effect.
The research nurse or a member of the research team will
ask each participant if they are experiencing any possible
side effects on day 4, 7, and 14 of the study when breast
milk samples are collected. Infants will be monitored as
per the Neonatal Intensive Care Unit standard of care and
their clinical condition will be evaluated daily as part of
medical rounds.
The current standard of care at the IWK Health Centre
Neonatal Intensive Care Unit does not recommend phar-
macological management for lactation failure. The use of
domperidone is based on the individual management
practices of each woman's physician. There will be no
study restrictions regarding the continued use of domperi-
done following the two-week study period. Any decision
to do so would occur based on discussions between the
participant and her family doctor. A letter informing the
participant and the family doctor which study arm the
participant had been randomized to will be sent following
completion of the study.
Study timeline
The initial preparation time for this study will be two
weeks. During that time, information will be given to the
staff of the Neonatal Intensive Care Unit regarding study
protocol. Approximately 60 infants less than 31 weeks
gestation are admitted to IWK yearly. Of these 20–25 per-
cent are multiples. Breast-feeding initiation rates are 80–
85 percent in our nursery. If half of these women experi-
ence difficulty with breast milk supply, 20–23 women a
year will be eligible for the study. Recruitment rates are
expected to be greater than 90 percent. Subject accrual and
data collection will extend over 24 months. It will take an
additional 4 months to analyze the data and prepare a
manuscript. The study results will be widely disseminated
through conference proceedings and peer reviewed publi-
cation. The total duration of the study is expected to be 28
months.
Discussion
The first participant was enrolled in October 2003. In June
of 2004 a Food and Drug administration (FDA, U.S.A.)
warning was issued regarding safety concerns related to
domperidone and lactating women. Seven women had
been enrolled at that time. The IWK Health Centre
Research Ethics Board was informed of the FDA warning
and enrollment was discontinued. A No Objection Letter
regarding the trial (Control # 093770) was issued by
Health Canada October 1, 2004 and Ethics Approval was
reinstated on October 5, 2004. An addendum was madeBMC Pregnancy and Childbirth 2006, 6:17 http://www.biomedcentral.com/1471-2393/6/17
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to the consent form outlining the concerns raised by the
FDA.
The FDA warning against the use of domperidone by lac-
tating women was based on case reports related to the
increased risk of cardiac arrhythmia and sudden death in
patients with malignant disease receiving high-dose intra-
venous domperidone therapy concurrently with chemo-
therapy and experiencing hypokalemia (serum potassium
levels between 2.0 and 3.3 mmol/L). In its oral form,
domperidone has been approved for use in Canada and
worldwide as a motility agent with an excellent safety
record. In a randomized trial, DaSilva et al determined
that in women receiving 10 mg of domperidone 3 times
daily to enhance lactation, the mean serum level on day 5
of therapy was 6.6 ng/mL [17]. The mean level of dom-
peridone excreted in the breast milk of these women was
1.2 ng/mL. No adverse effects to either mother or infants
were reported.
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